मूलभूत आँकड़े
| LEI | 2138006X34YDQ6OBYE79 |
| CIK | 1648257 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to HUTCHMED (China) Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addr |
|
| September 5, 2025 |
Exhibit 99.1 Press Release HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 Hong Kong, Shanghai & Florham Park, NJ — Friday, September 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be present |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 25, 2025 |
Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. HUTCHMED (China) L |
|
| August 25, 2025 |
HUTCHMED Announces Appointment of Acting Chief Executive Officer Exhibit 99.2 HUTCHMED Announces Appointment of Acting Chief Executive Officer Hong Kong, Shanghai & Florham Park, NJ — Monday, August 25, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Bo |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 20, 2025 |
Exhibit 99.1 Press Release HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China Hong Kong, Shanghai & Florham Park, NJ — Wednesday, August 20, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SANOVO, a China |
|
| August 7, 2025 |
Exhibit 99.1 HUTCHMED Reports 2025 Interim Results — Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal — Hong Kong, Shanghai & Florham Park, NJ — Thursday, August 7, 2025: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 7, 2025 |
Six Months Ended June 30, 2025 Exhibit 99.2 Dividends No dividend has been declared or paid by the Company since its incorporation. Reconciliation between US GAAP and International Financial Reporting Standards These interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP, which differ in certain respects from International Financial Reporting Standards (“IFRS”). The effects of mate |
|
| July 3, 2025 |
HUTCHMED to Announce 2025 Half-Year Financial Results Exhibit 99.1 HUTCHMED to Announce 2025 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 3, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| July 2, 2025 |
Update on Joint Corporate Brokers in London Exhibit 99.1 Update on Joint Corporate Brokers in London Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Deutsche Bank AG (trading as Deutsche Numis) as its joint Corporate Broker in London with immediate effect following the termination of HSBC Bank plc as joint Corporate Broker |
|
| June 30, 2025 |
Blocklisting Six Monthly Return Exhibit 99.1 Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ — Monday, June 30, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share |
|
| June 30, 2025 |
Exhibit 99.3 HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy — Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatm |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 30, 2025 |
Exhibit 99.2 Total Voting Rights Hong Kong, Shanghai & Florham Park, NJ — Monday, June 30, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) hereby notifies the market that as at June 30, 2025, the issued share capital of HUTCHMED consisted of 872,111,470 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The above f |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 10, 2025 |
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Exhibit 99.1 Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 10, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on June 9, 2025, it granted share options (“Share Options”) under the Share Option Scheme adopted by HUTCHMED in 2015 (the “Share Opt |
|
| June 5, 2025 |
Exhibit 99.1 Press Release HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma Hong Kong, Shanghai & Florham Park, NJ — Thursday, June 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that t |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 2, 2025 |
Exhibit 99.1 Press Release HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting — The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the data presented — Hong Kong, Sha |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| May 30, 2025 |
Exhibit 99.1 Total Voting Rights Hong Kong, Shanghai & Florham Park, NJ — Friday, May 30, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) hereby notifies the market that as at May 30, 2025, the issued share capital of HUTCHMED consisted of 871,611,095 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The above fig |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 27, 2025 |
Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong davispolk. |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 23, 2025 |
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting Exhibit 99.1 Press Release HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting Hong Kong, Shanghai & Florham Park, NJ — Friday, May 23, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be pre |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 13, 2025 |
Annual General Meeting held on May 13, 2025 – Poll Results Exhibit 99.1 Annual General Meeting held on May 13, 2025 – Poll Results Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 13, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual General Meeting (“AGM”) held on May 13, 2025 were duly passed. The poll results of the resoluti |
|
| April 24, 2025 |
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 Exhibit 99.1 Press Release HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 24, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be present |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 22, 2025 |
Exhibit 99.1 Press Release HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 22, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 7, 2025 |
Exhibit 99.6 April 08, 2025 HUTCHMED (China) Limited Please be advised of the following Final Depositary's Notice of Annual General Meeting of Shareholders: Depositary Receipt Information CUSIP: 44842L103 (DTC Eligible) ADS ISIN: US44842L1035 Country of Incorporation: Cayman Islands Meeting Details: Annual General Meeting on May 13, 2025, at 4:00 pm Hong Kong time (9:00 am London time) at 1st Floo |
|
| April 7, 2025 |
2024 Annual Report and Notice of Annual General Meeting Exhibit 99.2 2024 Annual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ — Monday, April 7, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2024 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”), will be posted on April 8, 2025 to those shareholders who have |
|
| April 7, 2025 |
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION Exhibit 99.4 THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional advisers. If you have sold or transferred all your shares in HUTCHMED (China) Limi |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 7, 2025 |
Exhibit 99.3 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. HUTCHMED (China) L |
|
| April 7, 2025 |
Exhibit 99.7 0 - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - 1.1 14475 ANNUAL GENERAL MEETING HUTCHMED (CHINA) LIMITED (Continued and to be signed on the reverse side) Electronic Shareholder Communications Please join the growing number of shareholders who receive emails instead of hard copy shareholder communications. Register onli |
|
| April 7, 2025 |
Exhibit 99.5 (Incorporated in the Cayman Islands with limited liability) (AIM/Nasdaq Code: HCM; HKEX Stock Code: 13) FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING I/We (note 1) of (address) being the registered holder(s) of (note 2) ordinary shares of US$0.10 each in the share capital of HUTCHMED (China) Limited (the “Company”), hereby appoint the Chairman of the meeting or (note 3) of (addr |
|
| March 31, 2025 |
Extraordinary General Meeting held on March 31, 2025 – Poll Results Exhibit 99.1 Extraordinary General Meeting held on March 31, 2025 – Poll Results Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 31, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that the ordinary resolution put to its Extraordinary General Meeting (“EGM”) held on March 31, 2025 was duly passed. Reference is made to the notice of EGM |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 21, 2025 |
Exhibit 99.1 Press Release HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma — First and only EZH2 inhibitor approved by the NMPA — —HUTCHMED’s fourth product, and its first approval in hematological malignancies — Hong Kong, Shanghai & Florham Park, NJ — Friday, March 21, 2025: HUTCHMED (China) Limited (“HUTCH |
|
| March 20, 2025 |
Exhibit 99.1 Press Release HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 — SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting — — Long-term survival |
|
| March 20, 2025 |
Exhibit 99.2 Intended Retirement of Independent Non-executive Directors and changes of composition of board committees Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 20, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors |
|
| March 20, 2025 |
6-K 1 hcm-20250320x6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Roa |
|
| March 19, 2025 |
Exhibit 12.1 CERTIFICATION I, Weiguo Su, certify that: 1.I have reviewed this annual report on Form 20-F of HUTCHMED (China) Limited (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| March 19, 2025 |
Exhibit 15.3 CONYERS DILL & PEARMAN 29th Floor One Exchange Square 8 Connaught Place Central Hong Kong T +852 2524 7106 | F +852 2845 9268 conyers.com March 19, 2025 Matter No.: 1006178 Doc Ref: 110671836 (852) 2842 9530 [email protected] HUTCHMED (China) Limited 48th Floor, Cheung Kong Center 2 Queen’s Road Central Hong Kong Dear Sirs, Re:HUTCHMED (China) Limited (the “Company”) Annual Rep |
|
| March 19, 2025 |
Exhibit 12.2 CERTIFICATION I, Cheng Chig Fung, Johnny, certify that: 1.I have reviewed this annual report on Form 20-F of HUTCHMED (China) Limited (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, n |
|
| March 19, 2025 |
Exhibit 99.2 Additional Information: Company Balance Sheets (Parent Company Only) December 31, Note 2024 2023 (in US$’000) Assets Current assets Cash and cash equivalents 98 65 Other receivables, prepayments and deposits 961 1,308 Total current assets 1,059 1,373 Investments in subsidiaries 817,364 795,326 Total assets 818,423 796,699 Liabilities and shareholders’ equity Current liabilities Other |
|
| March 19, 2025 |
Exhibit 13.1 906 Certification Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: In connection with the annual report of HUTCHMED (China) Limited (the “Company”) on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (the “Report”), I, Weiguo Su, the Chief Executive Officer of the Company, hereby certi |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 19, 2025 |
Exhibit 99.1 HUTCHMED Reports 2024 Full Year Results and Provides Business Updates 65% oncology products revenue growth drove profitable operation and supported new ATTC platform Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial results for the year ended December |
|
| March 19, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-240180, No. 333-224391 and No.333-212406) and Form F-3 (No. 333-280544) of HUTCHMED (China) Limited of our report dated March 19, 2025 relating to the financial statements and the effectiveness of internal control over financi |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 19, 2025 |
Exhibit 13.2 906 Certification Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: In connection with the annual report of HUTCHMED (China) Limited (the “Company”) on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (the “Report”), I, Cheng Chig Fung, Johnny, the Chief Financial Officer of the Company |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 19, 2025 |
Exhibit 99.1 Press Release HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 0 |
|
| March 19, 2025 |
Addendum to Dealing Code of HUTCHMED (China) Limited Exhibit 16.1 HUTCHMED CODE ON DEALINGS IN SHARES (“CODE”) INTRODUCTION The ordinary shares of HUTCHMED (China) Limited (the "Company", formerly known as “Hutchison China MediTech Limited”) have been admitted to trading on AIM in the United Kingdom and on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEX”) in Hong Kong and the Company's American depositary receipts are traded on the |
|
| March 19, 2025 |
CONSENT OF INDEPENDENT AUDITORS Exhibit 15.2 CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-240180, No. 333-224391 and No.333-212406) and Form F-3 (No. 333-280544) of HUTCHMED (China) Limited of our report dated March 19, 2025 relating to the financial statements of Shanghai Hutchison Pharmaceuticals Limited, which appears in this Annual Rep |
|
| March 14, 2025 |
Overseas Announcement – Adoption of the 2025 Long Term Incentive Plan Exhibit 99.2 Overseas Announcement – Adoption of the 2025 Long Term Incentive Plan HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from a voluntary announcement released to the Stock Exchange of Hong Kong Limited on March 14, 2025. The text relates to the adoption of the 2025 Long Term Incentive Plan with effect from April 24, 2025. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKE |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 14, 2025 |
Vesting of awards under the Long Term Incentive Plan Exhibit 99.1 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ — Friday, March 14, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on March 13, 2024 to the following person discharging managerial responsibilities were vested on March 1 |
|
| March 13, 2025 |
Notice of Extraordinary General Meeting Exhibit 99.1 Notice of Extraordinary General Meeting Hong Kong, Shanghai, & Florham Park, NJ — Thursday, March 13, 2025: HUTCHMED (China) Limited (“HUTCHMED”or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its Circular (including Notice of Extraordinary General Meeting) and the Form of Proxy (“EGM Materials”), will be posted on March 14, 2025 to those shareholders who have electe |
|
| March 13, 2025 |
Exhibit 99.4 (Incorporated in the Cayman Islands with limited liability) (AIM/Nasdaq Code: HCM; HKEX Stock Code: 13) FORM OF PROXY FOR USE AT THE EXTRAORDINARY GENERAL MEETING I/We (note 1) of (address) being the registered holder(s) of (note 2) ordinary shares of US$0.10 each in the share capital of HUTCHMED (China) Limited (the “Company”), hereby appoint the Chairman of the meeting or (note 3) o |
|
| March 13, 2025 |
Exhibit 99.2 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. HUTCHMED (China) L |
|
| March 13, 2025 |
Exhibit 99.6 0 - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - 1.1 14475 EXTRAORDINARY GENERAL MEETING HUTCHMED (CHINA) LIMITED (Continued and to be signed on the reverse side) Electronic Shareholder Communications Please join the growing number of shareholders who receive emails instead of hard copy shareholder communications. Regist |
|
| March 13, 2025 |
Exhibit 99.3 THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional advisers. If you have sold or transferred all your shares in HUTCHMED (China) Limi |
|
| March 13, 2025 |
Exhibit 99.5 March 14, 2025 HUTCHMED (China) Limited Please be advised of the following Final Depositary's Notice of Extraordinary General Meeting of Shareholders: Depositary Receipt Information CUSIP: 44842L103 (DTC Eligible) ADS ISIN: US44842L1035 Country of Incorporation: Cayman Islands Meeting Details: Extraordinary General Meeting on Monday, March 31, 2025 at 3:00 p.m. Hong Kong time (8:00 a. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 6, 2025 |
Exhibit 99.1 Press Release HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 6, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of its a Phase II trial of fanregrat |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 5, 2025 |
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Exhibit 99.1 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 5, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committ |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 3, 2025 |
Overseas Regulatory Announcement – Update on Transaction Exhibit 99.1 Overseas Regulatory Announcement – Update on Transaction HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on March 2, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The announcement provides an update on the proposed div |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| February 28, 2025 |
Overseas Regulatory Announcement – Update on Transaction Exhibit 99.1 Overseas Regulatory Announcement – Update on Transaction HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on February 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The text relates to the further update on dispatch |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| February 19, 2025 |
HUTCHMED to Announce 2024 Final Results Exhibit 99.1 HUTCHMED to Announce 2024 Final Results Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). |
|
| January 28, 2025 |
Overseas Regulatory Announcement – Disposal Transaction Exhibit 99.1 Overseas Regulatory Announcement – Disposal Transaction HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on January 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The text relates to the dispatch timing of the extrao |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| January 14, 2025 |
Exhibit 99.1 HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC — Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 14, 2025: HUTCHMED (China) Limited ( |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| January 2, 2025 |
Exhibit 99.3 Press Release HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy Hong Kong, Shanghai & Florham Park, NJ — Thursday, January 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New |
|
| January 2, 2025 |
Exhibit 99.1 HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED’s proprie |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| January 2, 2025 |
Overseas Regulatory Announcement – Disposal Transaction Exhibit 99.2 Overseas Regulatory Announcement – Disposal Transaction HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on January 1, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. As described in the HUTCHMED announcement entitled “HU |
|
| December 31, 2024 |
Appointment of Cavendish as Joint Corporate Broker in London Exhibit 99.1 Appointment of Cavendish as Joint Corporate Broker in London Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Cavendish Capital Markets Limited as its joint Corporate Broker in London with effect from January 1, 2025. Panmure Liberum Limited and HSBC Bank plc will |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 30, 2024 |
Blocklisting Six Monthly Return Exhibit 99.1 Blocklisting Six Monthly Return Hong Kong, Shanghai & Florham Park, NJ — Monday, December 30, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share |
|
| December 13, 2024 |
Exhibit 99.1 Press Release HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) — US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless o |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 12, 2024 |
Exhibit 99.1 Press Release HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy Hong Kong, Shanghai & Florham Park, NJ — Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 3, 2024 |
Exhibit 99.1 Press Release HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer — First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 3, 2024: HUTCHMED ( |
|
| November 29, 2024 |
Exhibit 99.2 Total Voting Rights Hong Kong, Shanghai & Florham Park, NJ — Friday, November 29, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) hereby notifies the market that as at November 29, 2024, the issued share capital of HUTCHMED consisted of 871,601,095 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The |
|
| November 29, 2024 |
Exhibit 99.1 Press Release HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administrat |
|
| November 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| November 22, 2024 |
Exhibit 99.1 Press Release HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan — Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — Hong Kong, Shanghai & Florham Park, NJ — Friday |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| November 20, 2024 |
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Exhibit 99.1 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 20, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Com |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| November 6, 2024 |
Exhibit 99.1 Press Release HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 6, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initi |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| October 31, 2024 |
Exhibit 99.2 Press Release HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda — US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it w |
|
| October 31, 2024 |
Exhibit 99.1 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Thursday, October 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at October 31, 2024, the issued share capital of HUTCHMED consisted of 871,561,945 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| October 21, 2024 |
Vesting of awards under the Long Term Incentive Plan Exhibit 99.1 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ — Monday, October 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on October 20, 2021 to the following persons discharging managerial responsibilities were vested on Oc |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| October 16, 2024 |
Exhibit 99.1 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial — New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this settin |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addr |
|
| September 24, 2024 |
Exhibit 99.1 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda — Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe and China — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 24, 2024: HUTC |
|
| September 9, 2024 |
Exhibit 99.1 Press Release HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer Hong Kong, Shanghai & Florham Park, NJ — Monday, September 9, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addr |
|
| August 30, 2024 |
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Exhibit 99.2 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Hong Kong, Shanghai & Florham Park, NJ — Friday, August 30, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination with paclitaxel for the treatment of se |
|
| August 30, 2024 |
Exhibit 99.1 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Friday, August 30, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at August 30, 2024, the issued share capital of HUTCHMED consisted of 871,469,720 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 22, 2024 |
Exhibit 99.1 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: HUTCHMED (China) Limited 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “ |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 21, 2024 |
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia Exhibit 99.1 Press Release HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia Hong Kong, Shanghai & Florham Park, NJ — Wednesday, August 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion leader in immune thrombocytopenia (“ITP”), to discuss the treatment landscape of ITP |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 6, 2024 |
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Exhibit 99.1 Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, August 6, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on August 5, 2024, it granted share options (“Share Options”) under the Share Option Scheme adopted by HUTCHMED in 2015 (the “Share |
|
| July 31, 2024 |
HUTCHMED Reports 2024 Interim Results and Provides Business Updates Exhibit 99.1 HUTCHMED Reports 2024 Interim Results and Provides Business Updates Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results |
|
| July 31, 2024 |
Six Months Ended June 30, 2024 Exhibit 99.2 Dividends No dividend has been declared or paid by the Company for the six months ended June 30, 2024 and 2023. Reconciliation between US GAAP and International Financial Reporting Standards These interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP, which differ in certain respects from International Financial Reporting Standards (“IFR |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| July 5, 2024 |
Exhibit 99.1 Press Release HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 4, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of |
|
| June 28, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form F-3 (Form Type) HUTCHMED (China) Limited (Exact Name of Registrant as Specified in its Charter) Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| June 28, 2024 |
Exhibit 99.2 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at June 28, 2024, the issued share capital of HUTCHMED consisted of 871,359,720 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The abov |
|
| June 28, 2024 |
Blocklisting Six Monthly Return Exhibit 99.1 Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 26, 2024 |
HUTCHMED to Announce 2024 Half-Year Financial Results Exhibit 99.1 HUTCHMED to Announce 2024 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 26, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Ko |
|
| June 24, 2024 |
Exhibit 99.1 HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda — Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — Hong |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 24, 2024 |
Exhibit 99.2 Press Release Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — Hong Kong, Shanghai & Florham Park, NJ — Monday, June 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, Jul |
|
| June 17, 2024 |
Exhibit 99.1 Press Release HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology — Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1 exposure — — Data supported regulatory submi |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 7, 2024 |
Exhibit 99.1 Press Release HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China Hong Kong, Shanghai & Florham Park, NJ — Friday, June 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignan |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| June 3, 2024 |
Exhibit 99.1 Press Release HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Hong Kong, Shanghai & Florham Park, NJ — Monday, June 3, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that results from FRUTIGA, HUTCHMED’s Phase III trial of |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address o |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 31, 2024 |
Exhibit 99.1 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Friday, May 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at May 31, 2024, the issued share capital of HUTCHMED consisted of 871,264,820 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. The above |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 24, 2024 |
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting Exhibit 99.1 Press Release HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting Hong Kong, Shanghai & Florham Park, NJ — Friday, May 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 17, 2024 |
Exhibit 99.2 HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees Hong Kong, Shanghai & Florham Park, NJ — Friday, May 17, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the |
|
| May 17, 2024 |
Exhibit 99.1 Press Release HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress Hong Kong, Shanghai & Florham Park, NJ — Friday, May 17, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovlepleni |
|
| May 14, 2024 |
Exhibit 99.2 Press Release HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China Hong Kong, Shanghai & Florham Park, NJ — Tuesday, May 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical t |
|
| May 14, 2024 |
Exhibit 99.1 Press Release HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui — Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufati |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| May 10, 2024 |
Annual General Meeting held on May 10, 2024 – Poll Results Exhibit 99.1 Annual General Meeting held on May 10, 2024 – Poll Results Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 10, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting (“AGM”) held on May 10, 2024 were duly passed. The poll results of the resol |
|
| May 8, 2024 |
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Exhibit 99.1 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Hong Kong, Shanghai & Florham Park, NJ — Wednesday, May 8, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company w |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address of |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 29, 2024 |
Exhibit 99.1 HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda — If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — Hong Kon |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 22, 2024 |
Vesting of awards under the Long Term Incentive Plan Exhibit 99.1 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ — Monday, April 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on April 20, 2020 to the following persons discharging managerial responsibilities were vested on April |
|
| April 8, 2024 |
Exhibit 99.6 April 09, 2024 HUTCHMED (China) Limited Please be advised of the following Final Depositary's Notice of Annual General Meeting of Shareholders: Depositary Receipt Information CUSIP: 44842L103 (DTC Eligible) ADS ISIN: US44842L1035 Country of Incorporation: Cayman Islands Meeting Details: Annual General Meeting on May 10, 2024 at 5:00 p.m. Hong Kong time (10:00 a.m. London time) at 1st |
|
| April 8, 2024 |
Exhibit 99.7 0 - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - 1.1 14475 ANNUAL GENERAL MEETING HUTCHMED (CHINA) LIMITED (Continued and to be signed on the reverse side) Electronic Shareholder Communications Please join the growing number of shareholders who receive emails instead of hard copy shareholder communications. Register onli |
|
| April 8, 2024 |
Exhibit 99.3 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (Іncorporated in t |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 8, 2024 |
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION Exhibit 99.4 THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional advisers. If you have sold or transferred all your shares in HUTCHMED (China) Limi |
|
| April 8, 2024 |
2023 ANNUAL REPORT Exhibit 99.1CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors TO Chi Keung, Simon, BSc, ACGI, MBA Chairman Weiguo SU, BSc, PhD Chief Executive Officer and Chief Scientific Officer CHENG Chig Fung, Johnny, BEc, CA Chief Financial Officer Non-executive Directors Dan ELDAR, BA, MA, MA, PhD Edith SHIH, BSE, MA, MA, EdM, Solicitor, FCG(CS, CGP), HKFCG(CS, CGP)(PE) Ling YAN |
|
| April 8, 2024 |
2023 Annual Report and Notice of Annual General Meeting Exhibit 99.2 2023 Annual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ — Monday, April 8, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2023 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”), will be posted on April 9, 2024 to those shareholders who have |
|
| April 8, 2024 |
Exhibit 99.5 (Incorporated in the Cayman Islands with limited liability) (AIM/Nasdaq Code: HCM; HKEX Stock Code: 13) FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING I/We (note 1) of (address) being the registered holder(s) of (note 2) ordinary shares of US$0.10 each in the share capital of HUTCHMED (China) Limited (the “Company”), hereby appoint the Chairman of the meeting or (note 3) of (addr |
|
| April 5, 2024 |
HUTCHMED Highlights Data to be Presented at AACR Congress 2024 Exhibit 99.1 Press Release HUTCHMED Highlights Data to be Presented at AACR Congress 2024 Hong Kong, Shanghai & Florham Park, NJ — Friday, April 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| April 2, 2024 |
Exhibit 99.1 Press Release HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status — NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 28, 2024 |
Exhibit 99.1 Press Release HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC — Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 con |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 22, 2024 |
Exhibit 99.1 Press Release HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Hong Kong, Shanghai & Florham Park, NJ — Friday, March 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of so |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 14, 2024 |
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Exhibit 99.1 Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Thursday, March 14, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on March 14, 2024, it granted share options (“Share Options”) under the Share Option Scheme adopted by HUTCHMED in 2015 (the “Share |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| March 5, 2024 |
Vesting of awards under the Long Term Incentive Plan Exhibit 99.1 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2023 annual results of HUTCHMED on February 28, 2024, the following awards granted under the Long Term Incentive Plan (“LTIP”) on March 26, 2021 to Dr Weig |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| February 28, 2024 |
Exhibit 12.2 CERTIFICATION I, Cheng Chig Fung, Johnny, certify that: 1. I have reviewed this annual report on Form 20-F of HUTCHMED (China) Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, |
|
| February 28, 2024 |
CONSENT OF INDEPENDENT ACCOUNTANTS Exhibit 15.2 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-240180, No. 333-224391 and No.333-212406) of HUTCHMED (China) Limited of our report dated February 28, 2024 relating to the financial statements of Shanghai Hutchison Pharmaceuticals Limited, which appears in this Annual Report on Form 20-F of HUTC |
|
| February 28, 2024 |
Additional Information: Company Balance Sheets (Parent Company Only) Exhibit 99.2 Additional Information: Company Balance Sheets (Parent Company Only) December 31, Note 2023 2022 (in US$’000) Assets Current assets Cash and cash equivalents 65 7,892 Other receivables, prepayments and deposits 1,308 947 Total current assets 1,373 8,839 Investments in subsidiaries 795,326 726,430 Total assets 796,699 735,269 Liabilities and shareholders’ equity Current liabilities Oth |
|
| February 28, 2024 |
Exhibit 15.3 CONYERS DILL & PEARMAN 29th Floor One Exchange Square 8 Connaught Place Central Hong Kong T +852 2524 7106 | F +852 2845 9268 conyers.com February 28, 2024 Matter No.: 838156 Doc Ref: 108779456 (852) 2842 9530 [email protected] HUTCHMED (China) Limited 48th Floor, Cheung Kong Center 2 Queen’s Road Central Hong Kong Dear Sirs, Re:HUTCHMED (China) Limited (the “Company”) Annual R |
|
| February 28, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-240180, No. 333-224391 and No.333-212406) of HUTCHMED (China) Limited of our report dated February 28, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears |
|
| February 28, 2024 |
Description of Ordinary Shares Exhibit 2.4 Description of Ordinary Shares The following are summaries of material provisions of our currently effective amended and restated memorandum and articles of association and the Cayman Islands Companies Act (As Revised), or the Companies Act, insofar as they relate to the material terms of our ordinary shares. You should read this summary together with our amended and restated memorandu |
|
| February 28, 2024 |
Exhibit 13.1 906 Certification Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: In connection with the annual report of HUTCHMED (China) Limited (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Weiguo Su, the Chief Executive Officer of the Company, hereby certi |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| February 28, 2024 |
Exhibit 99.1 HUTCHMED Reports 2023 Full Year Results and Provides Business Updates Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status and Breakthrough Therapy designation Hong Kong, Shanghai & Florham Park, |
|
| February 28, 2024 |
Exhibit 13.2 906 Certification Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: In connection with the annual report of HUTCHMED (China) Limited (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Cheng Chig Fung, Johnny, the Chief Financial Officer of the Company |
|
| February 28, 2024 |
HUTCHMED (CHINA) LIMITED COMPENSATION CLAWBACK POLICY Approved by the Board on October 2, 2023 Exhibit 15.4 HUTCHMED (CHINA) LIMITED COMPENSATION CLAWBACK POLICY Approved by the Board on October 2, 2023 1.Purpose. The purpose of this Policy is to set forth the circumstances under which Executive Officers of the Company will be required to repay or return certain Excess Awarded Compensation to members of the Company Group. The Company has adopted this Policy in accordance with the Clawback R |
|
| February 28, 2024 |
Exhibit 12.1 CERTIFICATION I, Weiguo Su, certify that: 1. I have reviewed this annual report on Form 20-F of HUTCHMED (China) Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| February 7, 2024 |
Exhibit 99.1 Press Release HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitax |
|
| February 2, 2024 |
Exhibit 99.1 Press Release HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership Hong Kong, Shanghai & Florham Park, NJ — Friday, February 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) has exercised options to license two drug candidates discovered b |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| February 1, 2024 |
HUTCHMED to Announce 2023 Final Results Exhibit 99.1 HUTCHMED to Announce 2023 Final Results Hong Kong, Shanghai & Florham Park, NJ — Thursday, February 1, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT). |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| January 30, 2024 |
Exhibit 99.1 Press Release HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer — First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of |
|
| January 11, 2024 |
Exhibit 99.1 Press Release HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status — NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocyto |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| December 29, 2023 |
Blocklisting Six Monthly Return Exhibit 99.1 Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: (a) Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHME |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 29, 2023 |
Exhibit 99.2 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at December 29, 2023, the issued share capital of HUTCHMED consisted of 871,256,270 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 21, 2023 |
Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. HUTCHMED (China) L |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 13, 2023 |
Exhibit 99.2 Press Release HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple renewal mechanism of the China Natio |
|
| December 13, 2023 |
Exhibit 99.1 Press Release HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III tri |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 7, 2023 |
Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. HUTCHMED (China) L |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| December 1, 2023 |
Exhibit 99.1 Press Release HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses Hong Kong, Shanghai & Florham Park, NJ — Friday, December 1, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatin |
|
| November 30, 2023 |
Exhibit 99.1 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Thursday, November 30, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at November 30, 2023, the issued share capital of HUTCHMED consisted of 871,172,770 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addre |
|
| November 9, 2023 |
Exhibit 99.1 HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer — FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S. approval of FRUZAQLA triggers first milestone payment from Taked |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| October 24, 2023 |
Vesting of awards under the Long Term Incentive Plan Exhibit 99.1 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 24, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on October 20, 2021 to the following persons discharging managerial responsibilities were vested on O |
|
| October 16, 2023 |
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023 Exhibit 99.1 Press Release HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023 Hong Kong, Shanghai & Florham Park, NJ — Monday, October 16, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presen |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addres |
|
| September 29, 2023 |
Exhibit 99.2 Press Release HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan — Third major market authorization application based on data from the FRESCO-2 global Phase III trial — Hong Kong, Shanghai & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) toda |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addr |
|
| September 29, 2023 |
Exhibit 99.1 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 29, 2023, the issued share capital of HUTCHMED consisted of 871,035,940 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addr |
|
| September 14, 2023 |
Exhibit 99.1 Director’s Share Dealing Hong Kong, Shanghai & Florham Park, NJ — Thursday, September 14, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) has received notifications that the spouse of Mr Graeme Jack, Independent Non-executive Director, sold a total of 3,000 American Depositary Shares of the Company (“ADSs”, each representing five Ordinary Shares |
|
| September 12, 2023 |
Exhibit 99.2 Press Release HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Addr |
|
| September 12, 2023 |
Exhibit 99.1 Press Release HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in Chi |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 31, 2023 |
Exhibit 99.1 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Thursday, August 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at August 31, 2023, the issued share capital of HUTCHMED consisted of 870,991,450 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury. Th |
|
| August 29, 2023 |
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer Exhibit 99.1 Press Release HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy D |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 24, 2023 |
HUTCHMED (China) Limited 48th Floor, Cheung Kong Center 2 Queen’s Road Central Hong Kong HUTCHMED (China) Limited 48th Floor, Cheung Kong Center 2 Queen’s Road Central Hong Kong August 24, 2023 VIA EDGAR Ms. |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| August 21, 2023 |
Exhibit 99.1 HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China — Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, where it was desig |
|
| August 7, 2023 |
Exercise of Share Options by a Director Exhibit 99.1 Exercise of Share Options by a Director Hong Kong, Shanghai & Florham Park, NJ — Monday, August 7, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has issued a total of 3,000,000 ordinary shares of US$0.10 each (“Ordinary Shares”) following the exercise of share options by Dr Weiguo Su, Executive Director, Chief Executive |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant’s name into English) 48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (Address |
|
| July 31, 2023 |
Exhibit 99.1 HUTCHMED Reports 2023 Interim Results and Provides Business Updates Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which include US$259 million of the upfront recognized from Takeda) Company |
